Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OTTx Peptide Candidate (Short Bowel) is a preclinical-stage therapeutic being developed by On Target Therapeutics for the treatment of short bowel syndrome (SBS). The drug is designed as a stable, long-acting peptide modulator of an unspecified G protein-coupled receptor (GPCR). The company's platform focuses on engineering peptide modulators with enhanced stability and extended duration of action compared to endogenous ligands, with the goal of improving therapeutic outcomes in gastrointestinal disorders. As of current reports, the program is in the preclinical phase, with the developer seeking industry partners for co-development to advance the candidate into Phase I or Phase II clinical trials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on OTTx Peptide Candidate (Short Bowel).